TELA Bio, Inc. (NASDAQ:TELA – Get Rating) insider Ew Healthcare Partners Fund 2, purchased 5,000 shares of the business’s stock in a transaction dated Friday, May 27th. The stock was bought at an average price of $7.43 per share, for a total transaction of $37,150.00. Following the completion of the acquisition, the insider now owns 3,455,709 shares of the company’s stock, valued at approximately $25,675,917.87. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Ew Healthcare Partners Fund 2, also recently made the following trade(s):

• On Wednesday, May 25th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The stock was acquired at an average cost of $6.87 per share, with a total value of $34,350.00.
• On Monday, May 23rd, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The stock was acquired at an average cost of $8.53 per share, with a total value of $42,650.00.
• On Friday, May 20th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The stock was acquired at an average cost of $8.79 per share, with a total value of $43,950.00.
• On Wednesday, May 18th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The stock was acquired at an average cost of $8.96 per share, with a total value of $44,800.00.
• On Monday, May 16th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The stock was acquired at an average cost of $8.61 per share, with a total value of $43,050.00.
• On Friday, May 13th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The stock was acquired at an average cost of $8.48 per share, with a total value of $42,400.00.
• On Wednesday, May 11th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The stock was acquired at an average cost of $8.82 per share, with a total value of $44,100.00.
• On Monday, May 9th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were purchased at an average cost of $9.38 per share, with a total value of $46,900.00.
• On Friday, May 6th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were purchased at an average cost of $9.55 per share, with a total value of $47,750.00.
• On Wednesday, May 4th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were purchased at an average cost of $9.53 per share, with a total value of $47,650.00.

Shares of TELA Bio stock traded up $0.36 during midday trading on Friday, hitting $7.36. The company had a trading volume of 48,698 shares, compared to its average volume of 34,878. The stock has a market cap of $107.15 million, a price-to-earnings ratio of -2.97 and a beta of 1.57. The company has a quick ratio of 3.26, a current ratio of 4.10 and a debt-to-equity ratio of 3.15. The company has a fifty day simple moving average of $9.82 and a 200 day simple moving average of $11.44. TELA Bio, Inc. has a 12-month low of $6.32 and a 12-month high of $16.53.

TELA Bio (NASDAQ:TELA – Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.25). TELA Bio had a negative net margin of 113.15% and a negative return on equity of 155.13%. During the same quarter in the previous year, the business earned ($0.56) earnings per share. As a group, analysts expect that TELA Bio, Inc. will post -2.47 EPS for the current year.

Several institutional investors have recently made changes to their positions in the stock. State Street Corp raised its position in shares of TELA Bio by 9.1% in the 1st quarter. State Street Corp now owns 26,065 shares of the company’s stock valued at $303,000 after purchasing an additional 2,167 shares during the last quarter. Velan Capital Investment Management LP increased its holdings in TELA Bio by 50.5% in the 1st quarter. Velan Capital Investment Management LP now owns 451,400 shares of the company’s stock worth $5,250,000 after buying an additional 151,400 shares during the period. Parkman Healthcare Partners LLC increased its holdings in TELA Bio by 4.0% in the 1st quarter. Parkman Healthcare Partners LLC now owns 108,504 shares of the company’s stock worth $1,262,000 after buying an additional 4,222 shares during the period. Vanguard Group Inc. increased its holdings in TELA Bio by 12.5% in the 1st quarter. Vanguard Group Inc. now owns 391,568 shares of the company’s stock worth $4,554,000 after buying an additional 43,633 shares during the period. Finally, WMS Partners LLC acquired a new position in TELA Bio in the 1st quarter worth approximately $327,000.

Several research firms have commented on TELA. Zacks Investment Research raised shares of TELA Bio from a “sell” rating to a “hold” rating in a research report on Tuesday. JMP Securities reissued a “buy” rating and set a $22.00 price target on shares of TELA Bio in a research report on Tuesday, March 22nd.

About TELA Bio (Get Rating)

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

Featured Stories

Receive News & Ratings for TELA Bio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TELA Bio and related companies with MarketBeat.com’s FREE daily email newsletter.